Does ACALABRUTINIB Cause Malignant neoplasm progression? 285 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 285 reports of Malignant neoplasm progression have been filed in association with ACALABRUTINIB (CALQUENCE). This represents 2.9% of all adverse event reports for ACALABRUTINIB.
285
Reports of Malignant neoplasm progression with ACALABRUTINIB
2.9%
of all ACALABRUTINIB reports
48
Deaths
31
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ACALABRUTINIB?
Of the 285 reports, 48 (16.8%) resulted in death, 31 (10.9%) required hospitalization, and 7 (2.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ACALABRUTINIB. However, 285 reports have been filed with the FAERS database.
What Other Side Effects Does ACALABRUTINIB Cause?
Death (1,857)
Fatigue (536)
Headache (534)
Product dose omission issue (349)
Diarrhoea (320)
Fall (289)
Contusion (270)
Dyspnoea (259)
Pneumonia (244)
Asthenia (243)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ACALABRUTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
ACALABRUTINIB vs ACAMPROSATE
ACALABRUTINIB vs ACARBOSE
ACALABRUTINIB vs ACCUTANE
ACALABRUTINIB vs ACEBUTOLOL
ACALABRUTINIB vs ACECLOFENAC